Outcome. Considering all events, including deaths unrelated to CML progression, outcome was inferior for older patients. All analyses were performed according to the intention-to-treat principle. EFS, FFS, PFS, and OS were calculated from the date of the first IM dose until any event (EFS), failure (FFS), progression to AP/BP or death (PFS), and death (OS). *Events and deaths: treatment failure or permanent discontinuation of IM for any reason, including toxicity, patient refusal, or loss to follow-up and deaths of any cause. †Failures (updated European LeukemiaNet recommendations²⁵ ) indicate no CHR at 3 months, no CyR at 6 months, < PCyR at 12 months, < CCyR at 18 months, loss of CHR or CCyR or progression to AP/BP, occurrence of CCA/Ph⁺, and occurrence of mutation poorly sensitive to IM at any time. Deaths indicate deaths of any cause. ‡Progressions indicate progressions to AB/BP. Deaths indicate deaths of any cause.